Everolimus induced pulmonary thromboembolism after kidney transplantation; a case report

Fereshteh Saddadi; Mohammad Hassan Fallahkohan

doi:10.34172/jnp.2022.11

J Nephropathol. 2022;11(1): e11.
doi: 10.34172/jnp.2022.11

Scopus ID: 85119583261

Abstract View: 1175

PDF Download: 480

Case Report

Everolimus induced pulmonary thromboembolism after kidney transplantation; a case report

Fereshteh Saddadi ¹^* , Mohammad Hassan Fallahkohan ²

¹ Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran
² Shahid Beheshti University of Medical Campus, Tehran, Iran

*Corresponding Author: *Corresponding author: Fereshteh Saddadi, Email: iumssaddadi@gmail.com, , Email: Saddadi.f@iums.ac.ir

Abstract

Choice of maintenance immunosuppressive therapy after renal transplantation is important for graft survival. However, complication may also occur. Venous thromboembolic event with the mTOR inhibitor (mTORi) everolimus is a rare but life-threatening complication. Here we describe a renal transplant recipient who developed pulmonary thromboembolism.

Keywords: Renal transplant, Everolimus, Pulmonary thromboembolisms

Implication for health policy/practice/research/medical education:

Paying attention to the major side effects of immunosuppressive drugs can be effective in selecting and preventing bad events.

Please cite this paper as: Saddadi F, Fallahkohan M. Everolimus induced pulmonary thromboembolism after kidney transplantation; a case report. J Nephropathol. 2022;11(1):e11. DOI: 10.34172/jnp.2022.11.